ReviewEuropean journal of pediatrics2026
Vitamin B12 in early childhood: a phenotype-guided approach to deficiency and unexpectedly elevated concentrations.
Review in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin B12 deficiency can cause preventable but potentially irreversible neurological injury in infancy, whereas unexpectedly elevated total vitamin B12 creates a different diagnostic challenge. This review outlines a phenotype-guided approach to both findings, emphasizing the mother-infant dyad. Infant deficiency commonly reflects low maternal status, including unrecognized malabsorption despite an omnivorous diet. Neurological manifestations may precede anemia or macrocytosis. Methylmalonic acid and total homocysteine therefore help resolve borderline or clinically discordant vitamin B12 results, although interpretation requires age-specific reference intervals and consideration of renal function. Symptomatic infants generally require prompt parenteral replacement, while selected asymptomatic infants with nutritional deficiency may respond to supervised oral treatment. Newborn screening can identify affected mother-infant dyads but does not exclude deficiency developing later during breastfeeding. Elevated total vitamin B12 most commonly reflects supplementation or altered transport, clearance, or assay characteristics, and should not be equated with toxicity. Persistent unexplained elevation warrants targeted clinical and laboratory assessment.
conclusionIntegrating clinical phenotype, maternal evaluation, functional biomarkers, and cautious interpretation of elevated concentrations may reduce delayed treatment and unnecessary investigations in infancy and early childhood. WHAT IS KNOWN: • Infant vitamin B12 deficiency may cause irreversible neurological injury without macrocytic anemia. • Maternal vitamin B12 status strongly influences fetal stores and breastfed-infant risk. WHAT IS NEW: • A phenotype-led framework integrates infant deficiency, maternal assessment, newborn screening, and unexpectedly elevated vitamin B12. • Functional biomarkers help distinguish intracellular deficiency from isolated high total vitamin B12, which is not equivalent to toxicity.
Indexed as
Identifiers
42825811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.